ANI Pharmaceuticals Management
Management criteria checks 3/4
ANI Pharmaceuticals' CEO is Nikhil Lalwani, appointed in Sep 2020, has a tenure of 3.67 years. total yearly compensation is $8.08M, comprised of 9.5% salary and 90.5% bonuses, including company stock and options. directly owns 1.88% of the company’s shares, worth $26.51M. The average tenure of the management team and the board of directors is 2.5 years and 3.7 years respectively.
Key information
Nikhil Lalwani
Chief executive officer
US$8.1m
Total compensation
| CEO salary percentage | 9.5% |
| CEO tenure | 3.7yrs |
| CEO ownership | 1.9% |
| Management average tenure | 2.5yrs |
| Board average tenure | 3.7yrs |
Recent management updates
Recent updates
These 4 Measures Indicate That ANI Pharmaceuticals (NASDAQ:ANIP) Is Using Debt Reasonably Well
Feb 17
Additional Considerations Required While Assessing ANI Pharmaceuticals' (NASDAQ:ANIP) Strong Earnings
Nov 15Does ANI Pharmaceuticals (NASDAQ:ANIP) Have A Healthy Balance Sheet?
Sep 22Does ANI Pharmaceuticals (NASDAQ:ANIP) Have A Healthy Balance Sheet?
Feb 22We Think ANI Pharmaceuticals (NASDAQ:ANIP) Has A Fair Chunk Of Debt
Oct 28ANI Pharma launches generic Prochlorperazine maleate tablets
Aug 29ANI Pharmaceuticals' generic dexamethasone tablets get FDA approval
Aug 16ANI Pharmaceuticals Q2 2022 Earnings Preview
Aug 05ANI Pharmaceuticals (NASDAQ:ANIP) Is Making Moderate Use Of Debt
Apr 29ANI Pharmaceuticals: Back In The Buy Zone
Feb 08Is ANI Pharmaceuticals (NASDAQ:ANIP) Using Too Much Debt?
Nov 02CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$8m | US$764k | US$15m |
| Sep 30 2023 | n/a | n/a | US$10m |
| Jun 30 2023 | n/a | n/a | -US$8m |
| Mar 31 2023 | n/a | n/a | -US$28m |
| Dec 31 2022 | US$5m | US$737k | -US$50m |
| Sep 30 2022 | n/a | n/a | -US$69m |
| Jun 30 2022 | n/a | n/a | -US$65m |
| Mar 31 2022 | n/a | n/a | -US$63m |
| Dec 31 2021 | US$7m | US$715k | -US$43m |
| Sep 30 2021 | n/a | n/a | -US$22m |
| Jun 30 2021 | n/a | n/a | -US$17m |
| Mar 31 2021 | n/a | n/a | -US$15m |
| Dec 31 2020 | US$4m | US$199k | -US$23m |
Compensation vs Market: Nikhil's total compensation ($USD8.08M) is above average for companies of similar size in the US market ($USD5.67M).
Compensation vs Earnings: Nikhil's compensation has been consistent with company performance over the past year.
CEO
Nikhil Lalwani (45 yo)
3.7yrs
Tenure
US$8,078,353
Compensation
Mr. Nikhil Lalwani served as a Director of Association for Accessible Medicines. He served as the Chief Executive Officer of InvaGen Pharmaceuticals, Inc. since October 24, 2016. Mr. Lalwani is a seasoned...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 3.7yrs | US$8.08m | 1.88% $ 26.5m | |
| Senior VP of Finance & CFO | 8yrs | US$2.58m | 0.80% $ 11.2m | |
| Senior Vice President of Corporate Development & Strategy | 2.5yrs | US$1.90m | 1.44% $ 20.4m | |
| Senior Vp & Head of Rare Disease | 3.3yrs | US$1.91m | 0.35% $ 5.0m | |
| Senior Vice President of Generics | 3.3yrs | US$1.94m | 0.28% $ 4.0m | |
| Head of R&D | 2.5yrs | no data | 0.24% $ 3.4m | |
| Senior Vice President of Operations & Product Development | 8yrs | US$1.43m | 0.55% $ 7.8m | |
| Senior VP | 1.8yrs | no data | 0.28% $ 4.0m | |
| Senior VP & Chief Human Resources Officer | 1.7yrs | no data | 0.25% $ 3.5m | |
| Chief Compliance Officer & Head of Legal of Rare Disease | 2.3yrs | no data | no data | |
| Chief Medical Officer | 2.3yrs | no data | no data | |
| Senior VP & Head of Established Brands | 2.5yrs | no data | 0.16% $ 2.3m |
2.5yrs
Average Tenure
50yo
Average Age
Experienced Management: ANIP's management team is considered experienced (2.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 3.7yrs | US$8.08m | 1.88% $ 26.5m | |
| Head of R&D | 2.5yrs | no data | 0.24% $ 3.4m | |
| Independent Director | 3.8yrs | US$393.25k | 0.13% $ 1.8m | |
| Independent Director | 5yrs | US$407.21k | 0.18% $ 2.6m | |
| Independent Director | 6yrs | US$412.21k | 0.22% $ 3.2m | |
| Independent Director | 3.8yrs | US$395.75k | 0.17% $ 2.4m | |
| Independent Director | 2.2yrs | US$395.74k | 0.096% $ 1.4m | |
| Independent Director | less than a year | US$470.76k | 0.036% $ 509.9k |
3.7yrs
Average Tenure
61.5yo
Average Age
Experienced Board: ANIP's board of directors are considered experienced (3.7 years average tenure).